Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer

• Status: Completed
• Trial end date: 2009-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety of Alimta when used with chemoradiation in inoperable non small cell lung cancer

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
• Collaborator: Eli Lilly and Company
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Unresectable Stage II, IIIB or IV non small cell lung cancer. Evaluable disease on planning CT scan Zubrod 0-1 Weight loss equal to or less than 10% 3 months prior to diagnosis FEV1 greater than 1000cc Adequate hematologic, renal and hepatic functions

Exclusion Criteria:

• Small cell cancer Stage I non small cell cancer Prior chemotherapy or thoracic or lower neck radiatio therapy